Advertisement

Concept and Scientific Background of Personalized Medicine

  • Thomas BieberEmail author
Chapter

Abstract

Tailoring a treatment to the special needs of a given individual has always been the overall goal in life and medical sciences. Progress in our understanding the pathophysiology and genetics of complex diseases has strongly contributed to consider many diseases under a new light and to project more sofisticated therapeutic approaches. Providing the right drug at the right dosis to the right patient the right time point is the substantial basis for personalized medicine, away from the classical, more or less evidence based “one size fits for all” model. Although the goal of personalized medicine sound obvious for all stakeholders, the way to reach it remains highly complex and needs the development of many different tools, including biobanks and the identification and validation of biomarkers. We will assist to a progressive change in our definition of the diseases, moving from the phenotypic taxonomy to a molecular taxonomy. The ultimate result will end in a more or less pronounced stratification of complex diseases into variable groups of patients, all characterized by various combinations of phenotypic and endophenotypic profiles. Moreover, this new medical evolutionary process will also induce a shift from the current curative medicine towards a more predictive, preventive, personalized and participatory (P4) medicine.

Keywords

Atopic Dermatitis Personalized Medicine Molecular Taxonomy Putative Therapeutic Target System Biologic Approach 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Roden DM, Tyndale RF. Genomic medicine, precision medicine, personalized medicine: what’s in a name? Clin Pharmacol Ther. 2013;94(2):169–72.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Bieber T. Stratified medicine: a new challenge for academia, industry, regulators and patients. London: Future Science; 2013.CrossRefGoogle Scholar
  4. 4.
    Shen B, Hwang J. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin Pharmacol Ther. 2010;88(6):754–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn. 2003;3(5):573–85.CrossRefPubMedGoogle Scholar
  6. 6.
    Eng C. Molecular genetics to genomic medicine practice: at the heart of value-based delivery of healthcare. Mol Genet Genomic Med. 2013;1(1):4–6.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics. 2004;18(4):322–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy. 2012;67(8):969–75.CrossRefPubMedGoogle Scholar
  10. 10.
    Suarez-Farinas M, Shah KR, Haider AS, Krueger JG, Lowes MA. Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. BMC Dermatol. 2010;10:1.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Broder S, Venter JC. Whole genomes: the foundation of new biology and medicine. Curr Opin Biotechnol. 2000;11(6):581–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Ocana A, Pandiella A. Personalized therapies in the cancer “omics” era. Mol Cancer. 2010;9:202.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med. 2013;5(1):73–82.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Bieber T, Broich K. Personalised medicine. Aims and challenges. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(11):1468–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Dorfman R, Khayat Z, Sieminowski T, Golden B, Lyons R. Application of personalized medicine to chronic disease: a feasibility assessment. Clin Transl Med. 2013;2(1):16.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    van den Broek M, Visser K, Allaart CF, Huizinga TW. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol. 2013;13(3):463–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–93.CrossRefPubMedGoogle Scholar
  18. 18.
    Olson JE, Bielinski SJ, Ryu E, Winkler EM, Takahashi PY, Pathak J, et al. Biobanks and personalized medicine. Clin Genet. 2014;86:50–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Suh KS, Sarojini S, Youssif M, Nalley K, Milinovikj N, Elloumi F, et al. Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine. J Oncol. 2013;2013:368751.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Fernald GH, Capriotti E, Daneshjou R, Karczewski KJ, Altman RB. Bioinformatics challenges for personalized medicine. Bioinformatics. 2011;27(13):1741–8.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009;326(5960):1694–7.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190–2.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Momper JD, Wagner JA. Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development. Clin Pharmacol Ther. 2014;95(2):138–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Robison JE, Perreard L, Bernard PS. State of the science: molecular classifications of breast cancer for clinical diagnostics. Clin Biochem. 2004;37(7):572–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475–82.PubMedGoogle Scholar
  26. 26.
    Morgan XC, Huttenhower C. Chapter 12: Human microbiome analysis. PLoS Comput Biol. 2012;8(12):e1002808.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Kesselheim AS, Shiu N. The evolving role of biomarker patents in personalized medicine. Clin Pharmacol Ther. 2014;95(2):127–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Schleidgen S, Marckmann G. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system. BMC Med Ethics. 2013;14:20.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014;16(3):251–7.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Koelsch C, Przewrocka J, Keeling P. Towards a balanced value business model for personalized medicine: an outlook. Pharmacogenomics. 2013;14(1):89–102.CrossRefPubMedGoogle Scholar
  31. 31.
    Hayes DF, Markus HS, Leslie RD, Topol EJ. Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Med. 2014;12:37.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, Roca J, et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med. 2011;3(7):43.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatology and AllergyCenter of Translational Medicine, University of BonnBonnGermany

Personalised recommendations